Infections caused by viridans streptococci in patients with neutropenia

Clinical Infectious Diseases

Volumn 34, Issue 11, 2002, Pages 1524-1529

  Tunkel, Allan R ^a   Sepkowitz, Kent A ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; COTRIMOXAZOLE; CYTARABINE; ERYTHROMYCIN; IMIPENEM; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CANCER; CLINICAL ARTICLE; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; STREPTOCOCCUS INFECTION; STREPTOCOCCUS MITIS;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; FLUOROQUINOLONES; HUMANS; NEUTROPENIA; RISK FACTORS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0036604476     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/340402     Document Type: Article

References (34)

1. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria
2. Viridans streptococci and groups C and G streptococci
3. Bacteremia due to viridans streptococci in neutropenic patients: A review
4. Viridans-group streptococcal infections in immunocompromised hosts
5. Alpha-hemolytic streptococci: Clinical significance in the cancer patient
6. Streptococcus salivarius sepsis in children with malignancies
7. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors
8. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors
9. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation
10. Viridans streptococcal shock syndrome during bone marrow transplantation
11. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia
12. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy: A review of 55 cases
13. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis
14. Viridans streptococcal bacteraemia in patients with haematological and solid malignancies
15. Viridans streptococcal bacteraemia in patients with neutropenia
16. Cystosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: A 5-year prospective study
17. The impact of mucositis on α-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies
18. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer
19. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients
20. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir
21. Risk factors for streptococcal septicaemia after marrow transplantation
22. Viridans streptococcal shock in bone marrow transplantation patients
23. Streptococcal septicemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy
24. Viridans streptococcal isolates from patients with septic shock induce tumor necrosis factor-alpha production from murine macrophages
25. Levels of cytokines and cytokine inhibitors in the neutropenic patient with α-hemolytic streptococcus shock syndrome
26. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States
27. Bacteremia due to viridans streptococci that are highly resistant to penicillin: Increase among neutropenic patients with cancer
28. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients
29. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients
30. Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antimicrobials
31. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: Relationship to a change in empirical antibiotic therapy in febrile neutropenia
32. In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group streptococci isolated from blood of neutropenic patients with cancer
33. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials
34. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: Analysis of risk factors and outcome in 60 patients from a single cancer center before and after penicillin is used for prophylaxis